Z-Medica Awarded $2.9 Million US Navy/Marine Corp Contract for Penetrating Wound Study Using its New Hemostatic Gauze

Wallingford, Conn. October 13, 2008 -- Z-Medica Corporation (Z-Medica), a medical products company focused on innovative hemostatic nano-technologies, today announced that it has been awarded a $2.9 million contract from the United States Navy and Marine Corps to fund large-scale human studies on stopping bleeding in penetrating wounds, using the company's new QuikClot® Combat Gauze™. The U.S. Department of Defense Committee on Tactical Combat Casualty Care recently selected QuikClot® Combat Gauze™ as the firstline hemorrhage treatment for tourniquet-resistant wounds for all branches of the U.S. military.
QuikClot(r) Combat Gauze(tm)
The clinical studies will take place at five major university and hospital trauma centers: Johns Hopkins University in Baltimore; the University of Miami; the University of Massachusetts Medical School in Worcester, Mass.; Vanderbilt University in Nashville; and Hartford Hospital in Hartford, Conn. Specifically, the study will address small entry/large exit wounds from high velocity bullets, traumatic injuries frequently encountered on the battlefield.